BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther 2020;5:230. [PMID: 33028805 DOI: 10.1038/s41392-020-00324-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang G, Xu Q, Wan Y, Zhang L, Wang Z, Meng F. miR-193a-3p Enhanced the Chemosensitivity to Trametinib in Gallbladder Carcinoma by Targeting KRAS and Downregulating ERK Signaling. Cancer Biother Radiopharm 2021. [PMID: 34287012 DOI: 10.1089/cbr.2021.0016] [Reference Citation Analysis]
2 Zhu Z, Zhu Q, Cai D, Chen L, Xie W, Bai Y, Luo K. Golgi phosphoprotein 3 promotes the proliferation of gallbladder carcinoma cells via regulation of the NLRP3 inflammasome. Oncol Rep 2021;45:113. [PMID: 33907835 DOI: 10.3892/or.2021.8064] [Reference Citation Analysis]
3 Bian R, Dang W, Song X, Liu L, Jiang C, Yang Y, Li Y, Li L, Li X, Hu Y, Bao R, Liu Y. Rac GTPase activating protein 1 promotes gallbladder cancer via binding DNA ligase 3 to reduce apoptosis. Int J Biol Sci 2021;17:2167-80. [PMID: 34239347 DOI: 10.7150/ijbs.58857] [Reference Citation Analysis]
4 Xu S, Jiang C, Lin R, Wang X, Hu X, Chen W, Chen X, Chen T. Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy. J Exp Clin Cancer Res 2021;40:373. [PMID: 34823564 DOI: 10.1186/s13046-021-02186-0] [Reference Citation Analysis]
5 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
6 Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:343-50. [PMID: 33645367 DOI: 10.1080/13543784.2021.1897102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
7 Di Federico A, Rizzo A, Ricci AD, Frega G, Palloni A, Tavolari S, Brandi G. Nivolumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:325-32. [PMID: 33307866 DOI: 10.1080/13543784.2021.1863946] [Reference Citation Analysis]
8 Roy N, Kshattry M, Mandal S, Jolly MK, Bhattacharyya DK, Barah P. An Integrative Systems Biology Approach Identifies Molecular Signatures Associated with Gallbladder Cancer Pathogenesis. J Clin Med 2021;10:3520. [PMID: 34441816 DOI: 10.3390/jcm10163520] [Reference Citation Analysis]
9 Liu T, Li Q, Zhang W, Zhu Q. Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review. Front Oncol 2021;11:733955. [PMID: 34676166 DOI: 10.3389/fonc.2021.733955] [Reference Citation Analysis]
10 Li L, Ren T, Liu K, Li ML, Geng YJ, Yang Y, Li HF, Li XC, Bao RF, Shu YJ, Weng H, Gong W, Lau WY, Wu XS, Liu YB. Development and Validation of a Prognostic Nomogram Based on the Systemic Immune-Inflammation Index for Resectable Gallbladder Cancer to Predict Survival and Chemotherapy Benefit. Front Oncol 2021;11:692647. [PMID: 34268122 DOI: 10.3389/fonc.2021.692647] [Reference Citation Analysis]
11 Canale M, Monti M, Rapposelli IG, Ulivi P, Sullo FG, Bartolini G, Tiberi E, Frassineti GL. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. Cancers (Basel) 2021;13:5671. [PMID: 34830826 DOI: 10.3390/cancers13225671] [Reference Citation Analysis]
12 Wang S, Tong H, Su T, Zhou D, Shi W, Tang Z, Quan Z. CircTP63 promotes cell proliferation and invasion by regulating EZH2 via sponging miR-217 in gallbladder cancer. Cancer Cell Int 2021;21:608. [PMID: 34789260 DOI: 10.1186/s12935-021-02316-w] [Reference Citation Analysis]
13 Cui XY, Li XC, Cui JJ, Wu XS, Zou L, Song XL, Ren T, Zhu YD, Li HF, Yang Y, Liu K, Han XS, Jia ZY, Wu WG, Wang XA, Gong W, Wang LW, Li ML, Liu YB. Modified FOLFIRINOX for unresectable locally advanced or metastatic gallbladder cancer, a comparison with GEMOX regimen. Hepatobiliary Surg Nutr 2021;10:498-506. [PMID: 34430528 DOI: 10.21037/hbsn-20-846] [Reference Citation Analysis]